On December 19, 2019, the US FDA approved Ervebo(R) (ebola zaire vaccine, live) intramuscular suspension indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. Approval is based off of a study conducted during the 2014-2016 outbreak in Guinea where Ervebo was determined to be 100% effective in preventing Ebola cases with symptom onset greater than 10 days after vaccination. Additionally, no cases of ebola virus disease with symptom onset greater than 10 days after vaccination were observed in the group immediately given the vaccine as opposed to 10 cases of ebola virus disease in the group who received a delayed vaccination.
Prescribing information can be found https://www.merck.com/product/usa/pi_circulars/e/ervebo/ervebo_pi.pdf.
Last Updated on